(2S,6S)-2-methyl-4-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]piperidin-4-ol
C17H17F6N3O — CID 168826647
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2S,6S)-2-methyl-4-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]piperidin-4-ol
(2S,6S)-2-methyl-4-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]piperidin-4-ol (PubChem CID 168826647) has the molecular formula C17H17F6N3O and a molecular weight of 393.33 g/mol. Its IUPAC name is (2S,6S)-2-methyl-4-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]piperidin-4-ol.
Molecular Properties
| Compound Name | (2S,6S)-2-methyl-4-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]piperidin-4-ol |
|---|---|
| PubChem CID | 168826647 |
| Molecular Formula | C17H17F6N3O |
| Molecular Weight | 393.33 g/mol |
| Exact Mass | 393.13 |
| IUPAC Name | (2S,6S)-2-methyl-4-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]piperidin-4-ol |
| SMILES | C[C@H]1CC(O)(c2ccc(C(F)(F)F)cc2)C[C@@H](c2cc(C(F)(F)F)n[nH]2)N1 |
| InChI | InChI=1S/C17H17F6N3O/c1-9-7-15(27,10-2-4-11(5-3-10)16(18,19)20)8-13(24-9)12-6-14(26-25-12)17(21,22)23/h2-6,9,13,24,27H,7-8H2,1H3,(H,25,26)/t9-,13-,15?/m0/s1 |
| InChIKey | ZWFOBECGMHOELJ-BQUZEMQQSA-N |
| XLogP | 4.15 |
| TPSA | 60.94 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 393.33 |
| LogP ≤ 5 | 4.15 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 168826647 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.